Fine Foods & Pharmaceuticals N.T.M. SpA (FF) AI Stock Analysis

• Market Cap: €218.52M
• Dividend Yield: 1.58%
• Average Volume (3M): 18.27K
• Price to Earnings (P/E): 17.6
• Beta (1Y): 0.25
• Revenue Growth: 1.00%
• EPS Growth: 376.92%
• Country: IT
• Employees: 779
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): 0.19
• Shares Outstanding: 22,060,125
• 10 Day Avg. Volume: 11,148
• 30 Day Avg. Volume: 18,273
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €12.10
• Price Target Upside: 36.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 73 Outperform
• Price Target: €9.50 ▲(7.47% Upside)

Fine Foods & Pharmaceuticals N.T.M. SpA demonstrates a strong technical position with bullish momentum, supported by reasonable valuation metrics. Financial performance shows recovery with improved profitability and leverage, but cash flow challenges remain a concern. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Improved Profitability

The improvement in net profit margin indicates better cost management and operational efficiency, enhancing long-term profitability.

Leverage Management

Better leverage management reduces financial risk and increases the company's ability to invest in growth opportunities.

Revenue Growth

Positive revenue growth reflects the company's ability to expand its market presence and attract new clients, supporting long-term stability.

Negative Factors

Negative Free Cash Flow

Negative free cash flow indicates potential challenges in funding operations and investments, which could hinder future growth.

Asset Management Risks

A decrease in total assets may signal inefficiencies in asset utilization, potentially impacting the company's ability to generate revenue.

Moderate Operational Efficiency

Moderate margins suggest there is room for improvement in operational efficiency, which is crucial for sustaining profitability.

Fine Foods & Pharmaceuticals N.T.M. SpA Business Overview & Revenue Model

Company Description

Fine Foods & Pharmaceuticals N.T.M. S.p.A. engages in the contract development and manufacturing of oral solid forms for the pharmaceutical and nutraceutical industries. It offers pharmaceutical products, including powders and granules, capsules, tablets, film-coated tablets, effervescent granules, and hard gelatine capsules. The company also provides nutraceutical products comprising soluble and effervescent powders and granules, soluble, effervescent and chewable tablets, fast melting/sublingual tablets, film-coated tablets, and hard gelatin capsules for various therapeutic areas, such as probiotics, multivitamins and minerals, immune systems, sleep and relax, gastrointestinal system, circulatory system, osteoarticular system, urinary system, women health, beauty, healthy ageing, and mental wellbeing. In addition, the company manufactures and trades in cosmetics products consisting of hair care, skin care, liquid detergents for personal hygiene, skin care emulsions, oral hygiene, deodorants, alcohol-based perfumery, bath and shower gel, shampoo and conditioners, shaping waxes, mouthwash and breath products, creams, gel and toothpaste, roll-on, stick and vapo spray deodrants, intimate cleansers, emulsions and microemulsions, gels, and liquid soaps; medical surgical aids and medical devices; antiseptics for undamaged skin, hand gel, pre-injection, hydroalcoholic surfaces, and iodine; and orthodontic cleaning tablets, disinfectants, and decongestant nasal sprays. The company was founded in 1984 and is headquartered in Verdellino, Italy.

How the Company Makes Money

Fine Foods & Pharmaceuticals N.T.M. SpA generates revenue through its contract development and manufacturing services. The company partners with various brands and companies, offering comprehensive services from product formulation to final packaging. Key revenue streams include manufacturing contracts for dietary supplements, pharmaceuticals, and cosmetics. The company's earnings are bolstered by its reputation for quality and innovation, which attracts long-term contracts with prominent clients. Additionally, FF may engage in strategic partnerships to expand its service offerings and enter new markets, further enhancing its revenue potential.

Fine Foods & Pharmaceuticals N.T.M. SpA Financial Statement Overview

Summary

Fine Foods & Pharmaceuticals N.T.M. SpA is showing signs of recovery with improved profitability and leverage metrics. The income statement reflects positive growth and margin improvements, while the balance sheet indicates better debt management. However, cash flow challenges persist, particularly with negative free cash flow, which could impact future investments and operational flexibility.

Income Statement

Fine Foods & Pharmaceuticals N.T.M. SpA has shown a consistent improvement in its gross profit margin, rising from 25.9% in 2022 to 38.9% in TTM 2025. The net profit margin has also improved to 3.9% in TTM 2025 from negative margins in previous years. Revenue growth is positive at 3.5% in TTM 2025, indicating a recovery from past declines. However, the EBIT and EBITDA margins, while improved, remain moderate, suggesting room for operational efficiency gains.

Balance Sheet

The company's debt-to-equity ratio has improved significantly from 0.90 in 2022 to 0.41 in TTM 2025, indicating better leverage management. Return on equity has also turned positive at 7.2% in TTM 2025, reflecting improved profitability. However, the equity ratio is not explicitly provided, and the company's total assets have decreased over the years, which could indicate potential risks in asset management.

Cash Flow

Operating cash flow remains strong, but free cash flow has been negative in recent periods, with a significant decline in TTM 2025. The free cash flow to net income ratio is positive, but the negative free cash flow growth rate of -281.7% in TTM 2025 is concerning. This suggests potential challenges in generating cash from operations and managing capital expenditures effectively.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	249.65M	243.75M	251.81M	206.85M	194.42M	173.03M
Gross Profit	103.97M	80.13M	68.56M	53.63M	55.89M	49.23M
EBITDA	35.36M	30.90M	19.29M	3.64M	9.86M	28.80M
Net Income	12.44M	8.16M	-3.52M	-9.50M	-1.43M	13.36M
Balance Sheet
Total Assets	270.27M	242.59M	241.56M	299.82M	302.81M	207.44M
Cash, Cash Equivalents and Short-Term Investments	21.90M	19.21M	19.15M	76.74M	95.09M	74.95M
Total Debt	73.53M	54.53M	66.39M	120.36M	110.76M	21.19M
Total Liabilities	133.10M	110.53M	114.61M	166.53M	155.59M	66.43M
Stockholders Equity	137.16M	132.06M	126.95M	133.29M	147.22M	141.01M
Cash Flow
Free Cash Flow	-4.70M	11.12M	-329.75K	-12.30M	-21.75M	14.66M
Operating Cash Flow	36.90M	45.85M	18.54M	3.69M	-5.83M	30.47M
Investing Cash Flow	-38.31M	-31.56M	45.89M	-15.31M	-36.35M	-12.34M
Financing Cash Flow	8.11M	-14.08M	-55.66M	4.74M	55.95M	-17.41M

Fine Foods & Pharmaceuticals N.T.M. SpA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:FF, the sentiment is Neutral. The current price of 8.84 is above the 20-day moving average (MA) of 8.81, above the 50-day MA of 8.51, and above the 200-day MA of 7.53, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 47.56 is Neutral, neither overbought nor oversold. The STOCH value of 34.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IT:FF.

Fine Foods & Pharmaceuticals N.T.M. SpA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VLS	75 Outperform	124.54M	14.83	9.15%	3.30%	2.66%	9.72%
FF	73 Outperform	€218.52M	17.58	―	1.58%	1.00%	376.92%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%